Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Income from Continuing Operations (2021 - 2025)

ARS Pharmaceuticals' Income from Continuing Operations history spans 5 years, with the latest figure at 41465000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 179.71% year-over-year to 41465000.0; the TTM value through Dec 2025 reached 179448000.0, down 10413.1%, while the annual FY2025 figure was 171298000.0, 2241.76% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 41465000.0 at ARS Pharmaceuticals, up from 53192000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 52020000.0 in Q4 2024 and bottomed at 53192000.0 in Q3 2025.
  • The 5-year median for Income from Continuing Operations is 18345500.0 (2023), against an average of 12204700.0.
  • The largest YoY upside for Income from Continuing Operations was 397.08% in 2023 against a maximum downside of 224.76% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 46623000.0 in 2021, then crashed by 133.12% to 15443000.0 in 2022, then surged by 397.08% to 45878000.0 in 2023, then grew by 13.39% to 52020000.0 in 2024, then plummeted by 179.71% to 41465000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Income from Continuing Operations are 41465000.0 (Q4 2025), 53192000.0 (Q3 2025), and 47614000.0 (Q2 2025).